MCID: ANG020
MIFTS: 64

Angiosarcoma

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angiosarcoma

MalaCards integrated aliases for Angiosarcoma:

Name: Angiosarcoma 12 74 58 36 54 6 15 39 17
Hemangiosarcoma 12 43 71

Characteristics:

Orphanet epidemiological data:

58
angiosarcoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare circulatory system diseases
Developmental anomalies during embryogenesis


External Ids:

Disease Ontology 12 DOID:0001816
KEGG 36 H01666
MeSH 43 D006394
NCIt 49 C3088 C9275
SNOMED-CT 67 39000009
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 72 C0018923
Orphanet 58 ORPHA263413
UMLS 71 C0018923 C0854893

Summaries for Angiosarcoma

KEGG : 36 Angiosarcomas are rare, generally aggressive, malignant mesenchymal tumours of vascular origin and constitute less than 1% of all sarcomas. Their most frequent site of origin is the head and neck, especially the scalp, of elderly men. Angiosarcomas are likely derived from vascular endothelial cells, possibly resulting from aberrant angiogenesis. Studies have shown relatively increased expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFr1-3) in human angiosarcoma. The most common gene mutation in angiosarcomas is KRAS as well as other RAS mutations. Activation of the RAS pathway is often tumorigenic. Although immortalised murine endothelial cells form benign haemangiomas in vivo, the addition of activated HRAS produces rapidly growing, poorly differentiated angiosarcomas.

MalaCards based summary : Angiosarcoma, also known as hemangiosarcoma, is related to liver angiosarcoma and prostate angiosarcoma. An important gene associated with Angiosarcoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ethiodized oil and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, liver and endothelial, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A vascular cancer that derives from the cells that line the walls of blood vessels or lymphatic vessels.

Wikipedia : 74 Angiosarcoma is a cancer of the endothelial cells that line the walls of blood vessels or lymphatic... more...

Related Diseases for Angiosarcoma

Diseases related to Angiosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 979)
# Related Disease Score Top Affiliating Genes
1 liver angiosarcoma 34.9 VIM TP53 PECAM1 KRAS
2 prostate angiosarcoma 34.5 VEGFA PECAM1 CD34
3 thyroid angiosarcoma 34.4 VWF PECAM1 CD34
4 central nervous system angiosarcoma 34.3 PECAM1 CD34
5 ovarian angiosarcoma 34.3 PECAM1 CD34
6 pediatric angiosarcoma 34.1 VWF VEGFA TP53 PECAM1 CD34
7 conventional angiosarcoma 33.9 PECAM1 CD34 CAMTA1
8 breast angiosarcoma 33.9 VEGFA TIE1 PECAM1 MYC KDR FLT4
9 lymphangiosarcoma 33.3 VWF VEGFA PECAM1 PDPN FLT4 CD34
10 intravascular papillary endothelial hyperplasia 33.1 VIM VEGFA
11 hemangioendothelioma 32.5 FLT4 FLI1 CD34 CAMTA1
12 epithelioid hemangioendothelioma 32.5 VEGFA KDR FLT1 CAMTA1 CALB2
13 kaposiform hemangioendothelioma 32.3 VWF PECAM1 KDR FLT4 FLI1 CD34
14 kaposi sarcoma 31.4 VEGFA TP53 MYC KDR FLT4
15 heart sarcoma 31.0 PECAM1 KIT CD34
16 spindle cell sarcoma 30.9 VIM VEGFA MUC1 CD34
17 mature teratoma 30.9 TP53 KRAS KIT
18 fibrosarcoma 30.9 VIM TP53 MYC KIT
19 pneumothorax 30.8 VIM MUC1 KDR CALB2
20 pyogenic granuloma 30.8 TEK KRAS CD34
21 benign mesothelioma 30.8 PECAM1 CD34 CALB2
22 mesenchymal cell neoplasm 30.8 TP53 PECAM1 KIT CD34
23 malignant fibrous histiocytoma 30.7 VIM TP53 MUC1 KIT
24 congenital lymphedema 30.7 PDPN FLT4
25 teratoma 30.7 VIM TP53 KRAS KIT CALB2
26 arteriovenous malformation 30.7 VEGFA TIE1 TEK KRAS
27 embryonal sarcoma 30.7 VIM TP53 KIT
28 rectum adenocarcinoma 30.6 TP53 MYC KRAS
29 adenosarcoma 30.6 VIM TP53 KIT
30 fibrous histiocytoma 30.6 VIM TP53 PECAM1 KIT CD34
31 exanthem 30.6 VEGFA KRAS KIT KDR
32 histiocytoid hemangioma 30.5 PECAM1 CD34 CAMTA1
33 squamous cell carcinoma 30.5 VEGFA TP53 PDPN MYC MUC1
34 hemangiopericytoma, malignant 30.5 VIM PECAM1 MUC1 KIT CD34
35 acquired immunodeficiency syndrome 30.4 TP53 PECAM1 MYC CD34
36 intestinal obstruction 30.4 VEGFA KIT CD34
37 varicose veins 30.4 VWF VEGFA KDR
38 neurilemmoma 30.3 VIM MUC1 KIT CD34 CALB2
39 breast sarcoma 30.3 TP53 PECAM1 CD34
40 serous cystadenocarcinoma 30.3 VEGFA TP53 KRAS
41 mucinous cystadenocarcinoma 30.3 VIM PDPN MUC1
42 thrombotic microangiopathy 30.3 VWF VEGFA
43 skin sarcoma 30.3 PECAM1 CD34
44 intramuscular hemangioma 30.3 TEK PECAM1 CD34
45 cholangiocarcinoma 30.3 TP53 MUC1 KRT8 KRAS
46 leiomyosarcoma 30.3 VIM VEGFA TP53 PECAM1 MYC MUC1
47 cystitis 30.3 VIM VEGFA TP53 KIT
48 cystic teratoma 30.3 TP53 KRAS KIT CALB2
49 malignant peripheral nerve sheath tumor 30.2 VIM TP53 MUC1 KIT CD34
50 papilloma 30.2 VEGFA TP53 KRT8 KRAS

Graphical network of the top 20 diseases related to Angiosarcoma:



Diseases related to Angiosarcoma

Symptoms & Phenotypes for Angiosarcoma

GenomeRNAi Phenotypes related to Angiosarcoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.7 KRAS
2 Decreased viability GR00055-A-2 9.7 KRAS
3 Decreased viability GR00055-A-3 9.7 KRAS
4 Decreased viability GR00106-A-0 9.7 KRAS
5 Decreased viability GR00221-A-1 9.7 KDR KIT KRAS MYC TIE1
6 Decreased viability GR00221-A-2 9.7 KDR KRAS
7 Decreased viability GR00221-A-3 9.7 KDR MYC
8 Decreased viability GR00221-A-4 9.7 KDR TIE1
9 Decreased viability GR00249-S 9.7 KDR MYC
10 Decreased viability GR00301-A 9.7 KIT KRAS
11 Decreased viability GR00342-S-1 9.7 TIE1
12 Decreased viability GR00342-S-2 9.7 TIE1
13 Decreased viability GR00342-S-3 9.7 TIE1
14 Decreased viability GR00381-A-1 9.7 KRAS
15 Decreased viability GR00402-S-2 9.7 MYC
16 Decreased cell migration GR00055-A-1 9.13 FLT1 TIE1 VIM

MGI Mouse Phenotypes related to Angiosarcoma:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.48 FLI1 FLT1 FLT4 KDR KIT KRAS
2 homeostasis/metabolism MP:0005376 10.41 CD34 FLT1 FLT4 KDR KIT KRAS
3 hematopoietic system MP:0005397 10.4 CD34 FLI1 FLT1 KDR KIT KRAS
4 immune system MP:0005387 10.4 CD34 FLI1 FLT1 FLT4 KDR KIT
5 growth/size/body region MP:0005378 10.38 CAMTA1 FLI1 FLT1 FLT4 KDR KIT
6 embryo MP:0005380 10.36 FLI1 FLT1 FLT4 KDR KIT KRAS
7 cellular MP:0005384 10.35 CD34 FLI1 FLT1 KDR KIT KRAS
8 mortality/aging MP:0010768 10.34 CAMTA1 FLI1 FLT1 FLT4 KDR KIT
9 digestive/alimentary MP:0005381 10.3 FLT4 KIT KRAS KRT8 MYC PDPN
10 muscle MP:0005369 10.25 FLI1 FLT1 FLT4 KDR KIT KRAS
11 integument MP:0010771 10.18 CD34 FLT4 KDR KIT KRAS MYC
12 nervous system MP:0003631 10.17 CALB2 CAMTA1 FLI1 FLT1 KDR KIT
13 liver/biliary system MP:0005370 10.16 FLI1 FLT4 KDR KIT KRAS KRT8
14 neoplasm MP:0002006 9.97 CAMTA1 CD34 FLI1 KIT KRAS MYC
15 normal MP:0002873 9.93 CALB2 CAMTA1 FLT1 FLT4 KDR KIT
16 no phenotypic analysis MP:0003012 9.86 FLT4 KDR KIT KRAS MYC TP53
17 reproductive system MP:0005389 9.65 CAMTA1 FLT1 FLT4 KIT KRAS KRT8
18 respiratory system MP:0005388 9.28 KDR KIT KRAS PDPN PECAM1 TIE1

Drugs & Therapeutics for Angiosarcoma

Drugs for Angiosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Ethiodized oil Approved, Investigational Phase 4 8008-53-5
2
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Ifosfamide Approved Phase 3 3778-73-2 3690
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
7
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
10
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Histamine Approved, Investigational Phase 3 51-45-6 774
13
Cyproheptadine Approved Phase 3 129-03-3 2913
14 Tubulin Modulators Phase 3
15 Antimitotic Agents Phase 3
16 Immunologic Factors Phase 3
17 Anti-Infective Agents Phase 3
18 Immunosuppressive Agents Phase 3
19 Antirheumatic Agents Phase 3
20
Isophosphamide mustard Phase 3 0
21 Etoposide phosphate Phase 3
22 Neurotransmitter Agents Phase 3
23
Liposomal doxorubicin Phase 2, Phase 3 31703
24 Anti-Bacterial Agents Phase 2, Phase 3
25 Antibiotics, Antitubercular Phase 2, Phase 3
26 Alkylating Agents Phase 2, Phase 3
27 Histamine Antagonists Phase 3
28 Anti-Allergic Agents Phase 3
29
Histamine Phosphate Phase 3 51-74-1 65513
30 Histamine H1 Antagonists Phase 3
31 Dermatologic Agents Phase 3
32 Gastrointestinal Agents Phase 3
33
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
34
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
35
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
37
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
38
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
39
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
40
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
41
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
42
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
43
Ipilimumab Approved Phase 2 477202-00-9
44
Pembrolizumab Approved Phase 2 1374853-91-4
45
Sunitinib Approved, Investigational Phase 1, Phase 2 557795-19-4, 341031-54-7 5329102
46
Metformin Approved Phase 2 657-24-9 14219 4091
47
Olaparib Approved Phase 2 763113-22-0 23725625
48
Adenosine Approved, Investigational Phase 2 58-61-7 60961
49
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
50
Cemiplimab Approved, Investigational Phase 2 1801342-60-8

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. A Phase IV Study. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
2 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
3 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 A Randomized Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (TAPPAS) Completed NCT02979899 Phase 3 Votrient
6 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
7 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
8 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
10 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
11 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
12 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
13 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
14 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma Unknown status NCT02212015 Phase 2 Pazopanib + Paclitaxel
17 Phase II Multicenter Stratified Study Evaluating the Efficacy and Toxicity of Sorafenib in Treating Locally Advanced or Metastatic Angiosarcomas That Are Not Accessible to Curative Surgery Unknown status NCT00874874 Phase 2 sorafenib tosylate
18 Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO) Unknown status NCT02732678 Phase 1, Phase 2 PROPRANOLOL
19 A Clinicopathological Phase II Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas Unknown status NCT01140737 Phase 2 Axitinib
20 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
21 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
22 Phase II Study, Multicenter, Randomized, Stratified, Evaluating the Efficacity of Weekly Paclitaxel, With or Without Bevacizumab in the Treatment of Metastatic or Locally Advanced Angiosarcomas Not Accessible to Surgery Treatment. Completed NCT01303497 Phase 2 Paclitaxel;Bevacizumab
23 An Open Label Multicenter Phase II Study of Bevacizumab for the Treatment of Angiosarcoma Completed NCT00288015 Phase 2
24 Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma Completed NCT01623869 Phase 2
25 Multicentric Phase II Study Evaluating the Efficacy and Toxicity of Weekly Paclitaxel in Locally Advanced or Metastatic Soft Tissue Angiosarcomas That Cannot be Treated by Surgery Completed NCT00217607 Phase 2 paclitaxel
26 Phase II Trial of BAY-9006 (NSC #724772) in Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
27 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
28 Phase II Trial Of Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2 gemcitabine;docetaxel;bevacizumab
29 A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma Completed NCT01975519 Phase 1, Phase 2 TRC105 and Pazopanib
30 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
31 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
32 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
33 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
34 Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment Completed NCT00041249 Phase 2 brostallicin
35 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
36 A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy Completed NCT00064220 Phase 2 soblidotin
37 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
38 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
39 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
40 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
41 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
42 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
43 MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
44 A Phase II Study of Talimogene Laherparepvec (T-VEC) in the Treatment of Locally Advanced Cutaneous Angiosarcoma Recruiting NCT03921073 Phase 2 T-VEC
45 Phase II Trial, Multicenter, First Line Paclitaxel-Avelumab Treatment for Inoperable Angiosarcoma Recruiting NCT03512834 Phase 2 Avelumab;Paclitaxel
46 A Pilot Phase 2 Study of Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) Recruiting NCT03331250 Phase 2 Eribulin
47 Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma Recruiting NCT03921008 Phase 1, Phase 2 Paclitaxel
48 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
49 A Phase II Study of Talimogene Laherparepvec (T-VEC) Administered Concurrently With the Anti-PD1 Monoclonal Antibody Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting NCT03069378 Phase 2 Talimogene Laherparepvec (T-VEC);Pembrolizumab
50 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin

Search NIH Clinical Center for Angiosarcoma

Cochrane evidence based reviews: hemangiosarcoma

Genetic Tests for Angiosarcoma

Anatomical Context for Angiosarcoma

MalaCards organs/tissues related to Angiosarcoma:

40
Breast, Liver, Endothelial, Bone, Heart, Spleen, Skin

Publications for Angiosarcoma

Articles related to Angiosarcoma:

(show top 50) (show all 6313)
# Title Authors PMID Year
1
Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face. 54 61
19913279 2010
2
Sporadic cutaneous angiosarcomas generally lack hypoxia-inducible factor 1alpha: a histologic and immunohistochemical study of 45 cases. 61 54
20123452 2010
3
Can lymphangiosarcoma be resurrected? A clinicopathological and immunohistochemical study of lymphatic differentiation in 49 angiosarcomas. 61 54
20459536 2010
4
Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations. 54 61
19182535 2009
5
Oral acantholytic squamous cell carcinoma shares clinical and histological features with angiosarcoma. 54 61
18671846 2008
6
[Retroperitoneal giant mixed sarcoma. Case report]. 61 54
18507961 2008
7
Podoplanin is a useful diagnostic marker for epithelioid hemangioendothelioma of the liver. 61 54
18084256 2008
8
Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. 61 54
18041747 2008
9
Cytokeratin and epithelial membrane antigen expression in angiosarcomas: an immunohistochemical study of 33 cases. 54 61
17284115 2007
10
Bilateral massive bloody pleurisy complicated by angiosarcoma. 54 61
17268128 2007
11
Intracranial angiosarcoma arising from a schwannoma. 61 54
16995966 2007
12
Observations on angiopoietin 2 in patients with angiosarcoma. 54 61
15149523 2004
13
[Oral adenoid squemous carcinoma. Tumor markers and prognosis]. 54 61
15045535 2004
14
Angiosarcoma of the larynx. Case report and review of the literature. 54 61
14677313 2003
15
Expression and function of the non-neuronal cholinergic system in endothelial cells. 54 61
12628465 2003
16
Actin-binding protein fascin expression in skin neoplasia. 54 61
12139639 2002
17
Epithelioid angiosarcoma of the pleura: a case report. 54 61
11748365 2001
18
Expression of vascular endothelial growth factor in a human hemangiosarcoma cell line (ISO-HAS). 61 54
11480589 2001
19
Angiosarcoma of the scalp: absence of vascular endothelial cadherin in primary and metastatic lesions. 54 61
11251578 2001
20
The non-neuronal cholinergic system in the endothelium: evidence and possible pathobiological significance. 61 54
11243570 2001
21
Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. 61 54
10854238 2000
22
[Podoplanin--a specific marker for lymphatic endothelium expressed in angiosarcoma]. 61 54
10714221 1999
23
Pseudomesotheliomatous angiosarcoma: a pleuropulmonary lesion simulating malignant pleural mesothelioma. 54 61
9181362 1997
24
[Primary renal epithelioid angiosarcoma with transitional cell carcinoma in renal pelvis]. 54 61
10374567 1997
25
Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. 54 61
8644848 1996
26
Multicentric epithelioid angiosarcoma of the bone. Pitfalls in clinical and morphological diagnosis. 54 61
9075571 1996
27
[A case of angiosarcoma with renal failure caused by recombinant interleukin-2 (rIL-2) and non-steroid anti-inflammatory drug (NSAID)]. 61 54
7776536 1995
28
Expression of VE (vascular endothelial)-cadherin and other endothelial-specific markers in haemangiomas. 61 54
7891227 1995
29
Pseudovascular adenoid squamous cell carcinoma of the skin. A neoplasm that may be mistaken for angiosarcoma. 61 54
1599022 1992
30
[Soft tissue angiosarcoma in a child. Immunohistochemical and ultrastructural features]. 61 54
1580939 1992
31
Immunoquantitation of von Willebrand factor (factor VIII-related antigen) in vinyl chloride exposed workers. 61 54
1739944 1992
32
The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. 61 54
1712541 1991
33
An immunohistochemical study of sarcomatoid liver carcinomas. 54 61
1710948 1991
34
Primary retroperitoneal angiosarcoma with eosinophilic globules. A combined light-microscopic, immunohistochemical, and ultrastructural study. 54 61
1693269 1990
35
Primary perirenal angiosarcoma: A preoperative diagnostic challenge. 61
32395430 2020
36
A rare case of multimetastatic cardiac angiosarcoma. 61
32577145 2020
37
Immunotherapy in sarcoma: combinations or single agents? In whom? 61
32541322 2020
38
A trimethoxy flavonoid isolated from stem extract of Tabebuia chrysantha suppresses angiogenesis in angiosarcoma. 61
32311118 2020
39
Successful Treatment of Urinary Bladder Hemangiosarcoma by Partial Cystectomy in a Dog. 61
32412336 2020
40
Imaging features of pathologically proven pediatric splenic masses. 61
32495175 2020
41
The incidence of skip metastases on whole bone MRI in high-grade bone sarcomas. 61
31919587 2020
42
Expression of Programmed Cell Death Proteins in Kaposi Sarcoma and Cutaneous Angiosarcoma. 61
32224717 2020
43
Carbon ion radiation therapy in breast cancer: a new frontier. 61
32318954 2020
44
Colonic Angiosarcoma: A Rare Gastrointestinal Malignancy. 61
30981006 2020
45
Serum anti-p53 autoantibodies in angiosarcoma. 61
32515022 2020
46
Gingival Angiosarcoma: A Case Report and Clinicopathologic Review of 32 Cases of Primary Gingival Angiosarcoma. 61
32523268 2020
47
TP53-Deficient Angiosarcoma Expression Profiling in Rat Model. 61
32532104 2020
48
Duodenal metastases of an angiosarcoma of the thyroid gland. 61
32544618 2020
49
Features of rare primary cardiac angiosarcoma in multimodality imaging. 61
32484217 2020
50
Patterns of Care and Survival of Cutaneous Angiosarcoma of the Head and Neck. 61
32043919 2020

Variations for Angiosarcoma

ClinVar genetic disease variations for Angiosarcoma:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MED12 NM_005120.3(MED12):c.130G>A (p.Gly44Ser)SNV other 92217 rs199469669 X:70339253-70339253 X:71119403-71119403
2 KRAS NM_033360.4(KRAS):c.57G>C (p.Leu19Phe)SNV Pathogenic/Likely pathogenic 217822 rs121913538 12:25398262-25398262 12:25245328-25245328
3 KRAS NM_033360.4(KRAS):c.57G>T (p.Leu19Phe)SNV Likely pathogenic 376034 rs121913538 12:25398262-25398262 12:25245328-25245328

Cosmic variations for Angiosarcoma:

9 (show top 50) (show all 1392)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM94290791 XIAP soft tissue,blood vessel,angiosarcoma,NS c.73G>C p.E25Q 23:123885735-123885735 3
2 COSM91383022 WT1 soft tissue,blood vessel,angiosarcoma,NS c.983G>A p.W328* 11:32416508-32416508 3
3 COSM87041278 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
4 COSM87029815 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.4585C>T p.R1529W 16:2085245-2085245 3
5 COSM87046601 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2494C>G p.H832D 16:2074338-2074338 3
6 COSM85723238 TSC1 soft tissue,blood vessel,angiosarcoma,NS c.1498C>T p.R500* 9:132906080-132906080 3
7 COSM85727534 TSC1 soft tissue,blood vessel,angiosarcoma,NS c.2716C>T p.Q906* 9:132897520-132897520 3
8 COSM85728656 TSC1 soft tissue,blood vessel,angiosarcoma,NS c.130A>C p.T44P 9:132927281-132927281 3
9 COSM88647601 TP63 soft tissue,blood vessel,angiosarcoma,NS c.1126C>T p.R376C 3:189868713-189868713 3
10 COSM87903333 TP53 soft tissue,liver,sarcoma,NS c.646G>A p.V216M 17:7674885-7674885 3
11 COSM87900239 TP53 soft tissue,blood vessel,angiosarcoma,NS c.422G>A p.C141Y 17:7675190-7675190 3
12 COSM87925845 TP53 soft tissue,blood vessel,angiosarcoma,NS c.733G>C p.G245R 17:7674230-7674230 3
13 COSM87897802 TP53 soft tissue,blood vessel,angiosarcoma,NS c.590T>G p.V197G 17:7674941-7674941 3
14 COSM87898431 TP53 soft tissue,blood vessel,angiosarcoma,NS c.451C>T p.P151S 17:7675161-7675161 3
15 COSM87900180 TP53 soft tissue,blood vessel,angiosarcoma,NS c.736A>G p.M246V 17:7674227-7674227 3
16 COSM87897924 TP53 soft tissue,blood vessel,angiosarcoma,NS c.413C>T p.A138V 17:7675199-7675199 3
17 COSM87899124 TP53 soft tissue,blood vessel,angiosarcoma,NS c.488A>G p.Y163C 17:7675124-7675124 3
18 COSM87906338 TP53 soft tissue,blood vessel,angiosarcoma,NS c.406C>T p.Q136* 17:7675206-7675206 3
19 COSM87900884 TP53 soft tissue,blood vessel,angiosarcoma,NS c.560-2A>T p.? 17:7674973-7674973 3
20 COSM87990610 TP53 soft tissue,blood vessel,angiosarcoma,NS c.412G>A p.A138T 17:7675200-7675200 3
21 COSM87941899 TP53 soft tissue,blood vessel,angiosarcoma,NS c.857A>T p.E286V 17:7673763-7673763 3
22 COSM87906844 TP53 soft tissue,blood vessel,angiosarcoma,NS c.472C>T p.R158C 17:7675140-7675140 3
23 COSM87912833 TP53 soft tissue,blood vessel,angiosarcoma,NS c.541C>T p.R181C 17:7675071-7675071 3
24 COSM87906440 TP53 soft tissue,blood vessel,angiosarcoma,NS c.718A>G p.S240G 17:7674245-7674245 3
25 COSM87899067 TP53 soft tissue,blood vessel,angiosarcoma,NS c.838A>G p.R280G 17:7673782-7673782 3
26 COSM87975568 TP53 soft tissue,liver,sarcoma,NS c.359A>T p.K120M 17:7676010-7676010 3
27 COSM87899145 TP53 soft tissue,blood vessel,angiosarcoma,NS c.763A>T p.I255F 17:7674200-7674200 3
28 COSM87898709 TP53 soft tissue,blood vessel,angiosarcoma,NS c.742C>T p.R248W 17:7674221-7674221 3
29 COSM87900565 TP53 soft tissue,blood vessel,angiosarcoma,NS c.1024C>T p.R342* 17:7670685-7670685 3
30 COSM87898301 TP53 soft tissue,blood vessel,angiosarcoma,NS c.438G>A p.W146* 17:7675174-7675174 3
31 COSM87915834 TP53 soft tissue,blood vessel,angiosarcoma,NS c.700T>C p.Y234H 17:7674263-7674263 3
32 COSM87898578 TP53 soft tissue,blood vessel,angiosarcoma,NS c.733G>A p.G245S 17:7674230-7674230 3
33 COSM88408170 TP53 soft tissue,blood vessel,angiosarcoma,NS c.491A>G p.K164R 17:7675121-7675121 3
34 COSM87949848 TP53 soft tissue,blood vessel,angiosarcoma,NS c.862A>T p.N288Y 17:7673758-7673758 3
35 COSM87905558 TP53 soft tissue,blood vessel,angiosarcoma,NS c.425C>T p.P142L 17:7675187-7675187 3
36 COSM87905916 TP53 soft tissue,blood vessel,angiosarcoma,NS c.818G>C p.R273P 17:7673802-7673802 3
37 COSM87917387 TP53 soft tissue,blood vessel,angiosarcoma,NS c.746G>C p.R249T 17:7674217-7674217 3
38 COSM87898714 TP53 soft tissue,blood vessel,angiosarcoma,NS c.844C>T p.R282W 17:7673776-7673776 3
39 COSM87976440 TP53 soft tissue,blood vessel,angiosarcoma,NS c.452C>T p.P151L 17:7675160-7675160 3
40 COSM87906968 TP53 soft tissue,blood vessel,angiosarcoma,NS c.833C>T p.P278L 17:7673787-7673787 3
41 COSM95878710 TGFBR2 soft tissue,blood vessel,angiosarcoma,NS c.934T>A p.W312R 3:30672042-30672042 3
42 COSM148034497 TCF7L2 soft tissue,blood vessel,angiosarcoma,NS c.1489C>T p.P497S 10:113165652-113165652 3
43 COSM92123235 SUZ12 soft tissue,blood vessel,angiosarcoma,NS c.1787C>T p.T596I 17:31995755-31995755 3
44 COSM88446927 STAT3 soft tissue,blood vessel,angiosarcoma,NS c.271C>T p.Q91* 17:42346571-42346571 3
45 COSM93992510 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 3
46 COSM88097765 SOX9 soft tissue,blood vessel,angiosarcoma,NS c.208C>T p.P70S 17:72121599-72121599 3
47 COSM89675617 SOX2 soft tissue,blood vessel,angiosarcoma,NS c.754C>T p.P252S 3:181713114-181713114 3
48 COSM101667904 SMARCD1 soft tissue,blood vessel,angiosarcoma,NS c.1510C>A p.Q504K 12:50098962-50098962 3
49 COSM89629521 SF3B1 soft tissue,blood vessel,other,benign c.2014G>T p.A672S 2:197402619-197402619 3
50 COSM93210564 RPS6KA4 soft tissue,blood vessel,angiosarcoma,NS c.1676C>T p.P559L 11:64369772-64369772 3

Expression for Angiosarcoma

Search GEO for disease gene expression data for Angiosarcoma.

Pathways for Angiosarcoma

Pathways related to Angiosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 VWF VIM VEGFA TP53 TEK PECAM1
2
Show member pathways
13.77 VIM VEGFA TP53 TIE1 TEK MYC
3
Show member pathways
13.69 TP53 TIE1 TEK MYC KRAS KIT
4
Show member pathways
13.69 VEGFA TP53 TIE1 TEK MYC KRAS
5
Show member pathways
13.53 VEGFA TP53 TIE1 TEK MYC KRAS
6
Show member pathways
13.42 TP53 TIE1 TEK KRAS KIT KDR
7
Show member pathways
13.35 VWF VIM VEGFA TP53 TEK MYC
8
Show member pathways
13.33 TIE1 TEK KRAS KIT KDR FLT4
9
Show member pathways
13.32 VWF VEGFA TP53 TEK PECAM1 PDPN
10
Show member pathways
13.31 TIE1 TEK KRAS KIT KDR FLT4
11
Show member pathways
13.27 VIM VEGFA TIE1 TEK KRAS KIT
12
Show member pathways
13.07 TP53 KRAS KIT KDR FLT4 FLT1
13
Show member pathways
12.94 TIE1 TEK KIT KDR FLT4 FLT1
14
Show member pathways
12.91 VWF VEGFA KRAS KDR FLT4 FLT1
15 12.84 VEGFA TP53 MYC KRAS KIT FLT4
16
Show member pathways
12.77 TP53 MYC KRAS KIT FLT4
17
Show member pathways
12.74 VEGFA TEK KRAS KIT KDR FLT4
18
Show member pathways
12.69 VWF VEGFA TP53 TEK MYC KRAS
19
Show member pathways
12.63 VEGFA TP53 MYC KRAS KDR
20
Show member pathways
12.6 TP53 TIE1 TEK MYC KRAS
21 12.58 VEGFA TP53 TEK MYC KRAS KIT
22 12.55 VIM VEGFA TP53 MYC KRAS
23
Show member pathways
12.51 TP53 KRAS KDR FLT4 FLT1
24
Show member pathways
12.45 TP53 KRAS KDR FLT4 FLT1
25
Show member pathways
12.44 VEGFA TP53 MYC MUC1 KRAS KDR
26
Show member pathways
12.42 VEGFA KRAS KDR FLT4 FLT1
27
Show member pathways
12.4 TIE1 TEK KRAS KIT KDR FLT4
28
Show member pathways
12.39 VEGFA KDR FLT4 FLT1
29 12.32 VEGFA TP53 MYC KRAS KDR
30 12.28 TP53 MYC FLT1 FLI1
31
Show member pathways
12.23 TP53 MYC KRAS KIT KDR FLT4
32 12.2 VEGFA TP53 MYC KRAS
33 12.16 VEGFA TP53 MYC KRAS
34 12.11 VEGFA TP53 PECAM1 KDR
35
Show member pathways
12.11 TP53 TIE1 TEK MYC KRAS KDR
36 12.08 VIM VEGFA MYC KDR
37 12.05 TIE1 TEK KIT KDR FLT4 FLT1
38 11.99 VIM VEGFA TP53 MYC MUC1
39
Show member pathways
11.88 VEGFA KDR FLT4 FLT1
40
Show member pathways
11.81 KRAS KIT KDR FLT4 FLT1
41 11.78 MYC KIT CD34
42 11.77 VEGFA TP53 MYC KRAS
43 11.74 TP53 MYC KRAS KIT
44 11.72 VEGFA TP53 KDR FLT1
45 11.57 VEGFA TP53 MYC
46 11.54 VEGFA MYC KRAS
47 11.35 VEGFA KDR FLT1
48
Show member pathways
11.34 KIT KDR FLT4 FLT1
49 11.14 VEGFA TEK KDR FLT1
50 11.12 VWF TEK PECAM1 PDPN KDR FLT4

GO Terms for Angiosarcoma

Cellular components related to Angiosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.09 VIM VEGFA TP53 TEK PECAM1 PDPN
2 membrane raft GO:0045121 9.65 TEK PECAM1 PDPN KRAS KDR
3 integral component of plasma membrane GO:0005887 9.65 TIE1 TEK PECAM1 PDPN MUC1 KIT
4 cell-cell junction GO:0005911 9.62 TEK PECAM1 KRT8 KIT
5 cell periphery GO:0071944 9.54 PECAM1 KRT8 CD34
6 receptor complex GO:0043235 9.1 TIE1 TEK KIT KDR FLT4 FLT1

Biological processes related to Angiosarcoma according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.22 VEGFA TIE1 TEK PDPN KIT KDR
2 regulation of transcription by RNA polymerase II GO:0006357 10.17 VEGFA TP53 MYC KIT FLI1 CAMTA1
3 phosphorylation GO:0016310 10.15 TIE1 TEK KIT KDR FLT4 FLT1
4 protein phosphorylation GO:0006468 10.12 TIE1 TEK KIT KDR FLT4 FLT1
5 positive regulation of cell proliferation GO:0008284 10.11 VEGFA MYC KRAS KIT KDR FLT4
6 negative regulation of apoptotic process GO:0043066 10.1 VEGFA TP53 TEK PDPN MYC KDR
7 positive regulation of gene expression GO:0010628 10.09 VIM VEGFA TP53 MYC KRAS KIT
8 negative regulation of gene expression GO:0010629 10.04 VEGFA TP53 MYC KDR CD34
9 protein autophosphorylation GO:0046777 10 TEK KIT KDR FLT4 FLT1
10 positive regulation of cell migration GO:0030335 9.99 VEGFA PECAM1 PDPN KIT KDR FLT1
11 in utero embryonic development GO:0001701 9.98 VEGFA TP53 TIE1 MYC
12 cytokine-mediated signaling pathway GO:0019221 9.98 VIM VEGFA TP53 MYC MUC1 KRAS
13 regulation of cell shape GO:0008360 9.95 VEGFA PDPN KIT KDR
14 positive regulation of protein phosphorylation GO:0001934 9.95 VEGFA TEK PECAM1 KRAS KDR FLT4
15 positive regulation of MAPK cascade GO:0043410 9.93 TEK KIT KDR FLT4 FLT1
16 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.91 TEK KIT KDR FLT1
17 positive regulation of endothelial cell proliferation GO:0001938 9.91 VEGFA TEK KDR FLT4
18 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.89 VEGFA KDR FLT4 FLT1
19 positive regulation of MAP kinase activity GO:0043406 9.88 VEGFA KRAS KIT FLT1
20 positive regulation of endothelial cell migration GO:0010595 9.88 VEGFA TEK KDR FLT4
21 positive regulation of angiogenesis GO:0045766 9.88 VEGFA TIE1 TEK KDR FLT1 CD34
22 angiogenesis GO:0001525 9.87 VEGFA TIE1 TEK PECAM1 KDR FLT4
23 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 VEGFA PECAM1 KIT
24 vasculogenesis GO:0001570 9.85 VEGFA TIE1 KDR
25 hematopoietic progenitor cell differentiation GO:0002244 9.85 TP53 KIT KDR FLT4 FLT1
26 peptidyl-tyrosine phosphorylation GO:0018108 9.85 TIE1 TEK KIT KDR FLT4 FLT1
27 ovarian follicle development GO:0001541 9.82 VEGFA MYC KIT
28 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.8 TEK KIT FLT1
29 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.8 VEGFA KDR FLT4 FLT1
30 positive regulation of focal adhesion assembly GO:0051894 9.79 VEGFA TEK KDR
31 positive regulation of vasculogenesis GO:2001214 9.7 KDR CD34
32 positive regulation of positive chemotaxis GO:0050927 9.7 VEGFA KDR
33 vascular wound healing GO:0061042 9.7 VEGFA KDR CD34
34 lymphangiogenesis GO:0001946 9.69 PDPN FLT4
35 positive regulation of protein kinase C signaling GO:0090037 9.69 VEGFA FLT4
36 positive regulation of cellular component movement GO:0051272 9.68 VEGFA PDPN
37 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.67 TP53 MUC1
38 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.67 VEGFA TP53
39 endothelium development GO:0003158 9.66 KDR CD34
40 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.66 VEGFA KDR
41 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.65 VEGFA KDR
42 glomerular endothelium development GO:0072011 9.63 PECAM1 CD34
43 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.63 TIE1 TEK KIT KDR FLT4 FLT1
44 vascular endothelial growth factor signaling pathway GO:0038084 9.56 VEGFA KDR FLT4 FLT1
45 sprouting angiogenesis GO:0002040 9.35 VEGFA TEK KDR FLT4 FLT1
46 positive regulation of kinase activity GO:0033674 9.1 TIE1 TEK KIT KDR FLT4 FLT1

Molecular functions related to Angiosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.39 VWF VIM VEGFA TP53 TIE1 TEK
2 kinase activity GO:0016301 9.88 TIE1 TEK KIT KDR FLT4 FLT1
3 protein kinase activity GO:0004672 9.85 TIE1 TEK KIT KDR FLT4 FLT1
4 protein tyrosine kinase activity GO:0004713 9.63 TIE1 TEK KIT KDR FLT4 FLT1
5 vascular endothelial growth factor binding GO:0038085 9.5 KDR FLT4 FLT1
6 vascular endothelial growth factor-activated receptor activity GO:0005021 9.43 KDR FLT4 FLT1
7 growth factor binding GO:0019838 9.35 TEK KIT KDR FLT4 FLT1
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.1 TIE1 TEK KIT KDR FLT4 FLT1

Sources for Angiosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....